A study to understand T2D patient characteristics with respect to medicines and clinical features

Phase 4

• Conditions: Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

• Registration Number: CTRI/2022/10/046335
• Lead Sponsor: ovo Nordisk Pharma Gulf FZE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

2.Male or female, age above or equal to 18 years at T2DM diagnosis

3.Year of birth 1928 or later (age <90 years old in 2017)

4.T2DM diagnosis in medical record on or after the date of local GLP-1 RA marketing authorization

5.Medical records documenting prior or ongoing treatment with metformin

6.Medical records documenting treatment with other non-metformin T2DM drugs

Exclusion Criteria

1.Previous participation in this study. Participation is defined as having given informed consent in this study.

2.Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

3.Patients with any diagnosis of type 1 diabetes mellitus (T1DM)

Study & Design

• Study Type: Observational
• Study Design: Not specified